# OnCo record amunix-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/amunix-pharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "amunix-pharmaceuticals" ;
  schema:name "Amunix Pharmaceuticals"@en ;
  schema:description "Amunix developed T-cell engager and cytokine cancer drugs with a protective mask that is clipped off by enzymes found in tumours, so the drugs become active mainly at the cancer. Sanofi agreed to buy the company in December 2021 for about $1 billion upfront."@en ;
  schema:url <https://onco.cc/companies/amunix-pharmaceuticals/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1121404/000119312521363409/d237650dex992.htm>, <https://www.sec.gov/Archives/edgar/data/1121404/000112140422000002/pressreleaseq42021english.htm>, <https://www.sec.gov/Archives/edgar/data/1121404/000119312521363409/d237650dex992.htm> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/cytokine-therapy/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/> .